Applied Therapeutics, Inc.

DB:2UV Stock Report

Market Cap: €13.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Applied Therapeutics Management

Management criteria checks 1/4

Applied Therapeutics' CEO is Les Funtleyder, appointed in Nov 2023, has a tenure of 2.25 years. total yearly compensation is $1.05M, comprised of 50.4% salary and 49.6% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth €43.87K. The average tenure of the management team and the board of directors is 1.5 years and 7.9 years respectively.

Key information

Les Funtleyder

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage50.35%
CEO tenure2.3yrs
CEO ownership0.3%
Management average tenure1.5yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Les Funtleyder's remuneration changed compared to Applied Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$18m

Jun 30 2025n/an/a

-US$68m

Mar 31 2025n/an/a

-US$44m

Dec 31 2024US$1mUS$531k

-US$106m

Sep 30 2024n/an/a

-US$187m

Jun 30 2024n/an/a

-US$161m

Mar 31 2024n/an/a

-US$194m

Dec 31 2023US$675kn/a

-US$120m

Sep 30 2023n/an/a

-US$97m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$80kn/a

-US$83m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$229kn/a

-US$106m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$104m

Mar 31 2021n/an/a

-US$106m

Dec 31 2020US$303kn/a

-US$94m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$625kn/a

-US$46m

Compensation vs Market: Les's total compensation ($USD1.05M) is above average for companies of similar size in the German market ($USD375.63K).

Compensation vs Earnings: Les's compensation has increased whilst the company is unprofitable.

CEO

Les Funtleyder (55 yo)

2.3yrs
Tenure
US$1,053,846
Compensation

Mr. Les D. Funtleyder has been an Independent Director of Reviva Pharmaceuticals Holdings, Inc. since December 8, 2020. Mr. Funtleyder served as Interm CEO, CFO, Principal Financial Officer & Independent D...

Leadership Team

NamePositionTenureCompensationOwnership
Les Funtleyder
Interm CEO2.3yrsUS$1.05m0.33%
€ 43.9k
Corwin Hooks
Chief Commercial Officer1.8yrsUS$2.18m0.053%
€ 7.1k
Constantine Chinoporos
COO & Chief Business Officer2.2yrsno data0.051%
€ 6.8k
Catherine Thorpe
Interim Chief Accounting Officer2.7yrsno datano data
Reena Colacot
Head of Quality1.1yrsno datano data
Todd Baumgartner
Chief Regulatory Officerless than a yearno datano data
Evan Bailey
Chief Medical Officerless than a yearno data0.36%
€ 47.2k
Dottie Caplan
Executive Vice President of Patient Advocacy & Government Affairs.less than a yearno datano data
1.5yrs
Average Tenure
58.5yo
Average Age

Experienced Management: 2UV's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Les Funtleyder
Interm CEO9.7yrsUS$1.05m0.33%
€ 43.9k
Jay Skyler
Independent Director6.8yrsUS$267.50k0.035%
€ 4.7k
Lawrence Steinman
Member of Scientific Advisory Boardno datano datano data
Teena Lerner
Lead Independent Director8.9yrsUS$265.00k0.069%
€ 9.2k
Stacy Kanter
Independent Director6.8yrsUS$267.50k0.035%
€ 4.7k
Gregg Stone
Member of Scientific Advisory Boardno datano datano data
Donald Landry
Chairman of Scientific Advisory Boardno datano datano data
Donald D'Amico
Member of Scientific Advisory Boardno datano datano data
Roy Freeman
Member of Scientific Advisory Boardno datano datano data
Roxana Mehran
Member of Scientific Advisory Boardno datano datano data
7.9yrs
Average Tenure
69yo
Average Age

Experienced Board: 2UV's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/03 11:25
End of Day Share Price 2026/01/28 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Applied Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Paul ChoiGoldman Sachs
Luke DavisRBC Capital Markets